Key result
Prestroke antiplatelet agent use was associated with initial mild stroke, reducing first-ever stroke severity.
Why the study?
Does prestroke antiplatelet agent use reduce initial stroke severity in patients with first-ever ischemic stroke?
Case-Control (n=3,025)
Does prestroke antiplatelet agent use reduce initial stroke severity in patients with first-ever ischemic stroke?
Prestroke use of antiplatelet agents is associated with decreased initial stroke severity in patients experiencing their first-ever acute ischemic stroke.
Answers are grounded in this paper and cite their sources.
May lessen initial severity in first-ever ischemic stroke; hypothesis-generating and requires prospective confirmation before any practice change.
OBJECTIVE: To investigate whether prestroke antiplatelet agent (PA) use was associated with initial stroke severity. METHODS: This was a retrospective, case-control study based on data from a prospectively collected hospital-based stroke registry (Korea University Stroke Registry). A total of 3,025 patients who were admitted with a diagnosis of first-ever ischemic stroke within 5 days of symptom onset were included. Stroke severity was measured with the NIH Stroke Scale (NIHSS). NIHSS score ≤4 at admission was categorized as mild stroke. Patients from the PA group were matched with those from the non-PA group using estimated propensity scores at a 1:1 ratio. Stepwise multivariable logistic regression analyses were performed on patients in the matched datasets with initial mild stroke. RESULTS: Patients' mean age was 66.3 ± 13.0 years, and 1,850 were men (61.5%). A total of 748 patients had been taking antiplatelet agents prior to stroke onset; 644 patients (86.1%) were taking a single antiplatelet agent. Among these agents, aspirin (83.7%) was the most common. A total of 102 patients (13.6%) were taking 2 antiplatelet agents. Multivariable analysis after propensity score matching demonstrated that PA use was associated with initial mild stroke (odds ratio 1.344; 95% confidence interval 1.014-1.782). CONCLUSIONS: PA use was associated with decreased first-ever stroke severity, suggesting that it has a beneficial effect. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that prestroke use of antiplatelet agents reduces stroke severity in patients with first-ever acute ischemic stroke.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2015) conducted a case-control in first-ever ischemic stroke (n=3,025). Prestroke antiplatelet agents vs. No prestroke antiplatelet agents was evaluated on initial mild stroke (NIHSS score ≤4 at admission) (OR 1.344, 95% CI 1.014-1.782). Prestroke antiplatelet agent use was associated with initial mild stroke, reducing first-ever stroke severity.
Synapse has enriched 10 related papers. Consider them for comparative context: